White Blood Cell Count, C-Reactive Protein, and Incident Heart Failure in the Atherosclerosis Risk in Communities (ARIC) Study

Annals of Epidemiology

Volumn 21, Issue 10, 2011, Pages 739-748

  Bekwelem, Wobo ^a,f   Lutsey, Pamela L ^a   Loehr, Laura R ^b   Agarwal, Sunil K ^b   Astor, Brad C ^c   Guild, Cameron ^d   Ballantyne, Christie M ^e   Folsom, Aaron R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b IL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

C Reactive Protein; Granulocytes; Heart Failure; Inflammation; Leukocytes; Prospective Study; Risk Factors

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; GRANULOCYTE; HEART FAILURE; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; PRIORITY JOURNAL;

C-REACTIVE PROTEIN; COHORT STUDIES; CORONARY DISEASE; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; LEUKOCYTE COUNT; MALE; MIDDLE AGED; RISK FACTORS;

EID: 80052267732     PISSN: 10472797     EISSN: 18732585     Source Type: Journal    
DOI: 10.1016/j.annepidem.2011.06.005     Document Type: Article

References (41)

1. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. Lancet 2010, 375:132-140. for the Emerging Risk Factors Collaboration.
2. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analysis. BMJ 2000, 321:199-204.
3. Madjid M., Awan I., Willerson J.T., Casscells S.W. Leukocyte count and coronary heart disease-implications for risk assessment. J Am Coll Cardiol 2004, 44:1945-1956.
4. Hofman A., Grobbee D.E., de Jong P.T., van den Ouweland F.A. Determinants of disease and disability in the elderly: The Rotterdam Elderly Study. Eur J Epidemiol 1991, 7:403-422.
5. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2000, 35:1628-1637.
6. Vasan R.S., Sullivan L.M., Roubenoff R., Dinarello C.A., Harris T., Benjamin E.J., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107:1486-1491. for the Framingham Heart Study.
7. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrrell K., et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC Study. Circulation 2003, 108:2317-2322.
8. Kardys I., Knetsch A.M., Bleumink G.S., Deckers J.W., Hofman A., Stricker B.H., et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J 2006, 152:514-520.
9. Bahrami H., Bluemke D.A., Kronmal R., Bertoni A.G., Lloyd-Jones D.M., Shahar E., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: The MESA (Multi-Ethnic Study of Atherosclerosis) Study. J Am Coll Cardiol 2008, 51:1775-1783.
10. Devaux B., Scholz D., Hirche A., Klövekorn W.P., Schaper J. Upregulation of cell adhesion molecules and the presence of low grade inflammation in human chronic heart failure. Eur Heart J 1997, 18:470-479.
11. Fildes J.E., Shaw S.M., Yonan N., Williams S.G. The immune system and chronic heart failure: Is the heart in control?. J Am Coll Cardiol 2009, 53:1013-1020.
12. Rauchhaus M., Doehner W., Francis D.P., Davos C., Kemp M., Liebenthal C., et al. Plasma cytokine parameters and mortality in patients with heart failure. Circulation 2000, 102:3060-3067.
13. Kaneko K., Kanda T., Yamauchi Y., Hasegawa A., Iwasaki T., Arai M., et al. C-reactive protein in dilated cardiomyopathy. Cardiology 1999, 91:215-217.
14. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., Mann D.L. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001, 103:2055-2059.
15. The Atherosclerosis Risk in Communities (ARIC) Study: Design and objectives. The ARIC Investigators. Am J Epidemiol 1989, 129:687-702.
16. Baecke J.A.H., Burema J., Frijters J.E. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 1982, 36:936-942.
17. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
18. Nieto F.J., Szklo M., Folsom A.R., Rock R., Mercuri M. Leukocyte count correlates in middle-aged adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Epidemiol 1992, 136:525-537.
19. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
20. Ballantyne C.M., Hoogeveen R.C., Bang H., Coresh J., Folsom A.R., Heiss G., et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2004, 109:837-842.
21. Eriksson H., Caidahl K., Larsson B., Ohlson L.O., Welin L., Wilhelmsen L., et al. Cardiac and pulmonary causes of dyspnea-Validation of a scoring test for clinical-epidemiological use: The Study of Men Born in 1913. Eur Heart J 1987, 8:1007-1014.
22. Loehr L.R., Rosamond W.D., Chang P.P., Folsom A.R., Chambless L.E. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities Study). Am J Cardiol 2008, 101:1016-1022.
23. Wilhelmsen L., Eriksson H., Svärdsudd K., Caidahl K. Improving the detection and diagnosis of congestive heart failure. Eur Heart J 1989, 10(Suppl C):13-18.
24. SAS 9.2 Software 2010, SAS Institute Inc, SAS Institute Inc., Cary, NC.
25. Tarone R.E. Tests for trend in life table analysis. Biometrika 1975, 62:679-682.
26. Suleiman M., Khatib R., Agmon Y., Mahamid R., Boulos M., Kapeliovich M., et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction: Predictive role of C-reactive protein. J Am Coll Cardiol 2006, 47:962-968.
27. Engström G., Melander O., Hedblad B. Leukocyte count and incidence of hospitalizations due to heart failure. Circ Heart Fail 2009, 2:217-222.
28. Cooper H.A., Exner D.E., Waclawiw M.A., Domanski M.J. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular dysfunction (an analysis of the Studies of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol 1999, 84:252-257.
29. Barron H.V., Cannon C.P., Murphy S.A., Braunwald E., Gibson M.C. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: A Thrombolysis In Myocardial Infarction 10 Substudy. Circulation 2000, 102:2329-2334.
30. Hasper D., Hummel M., Kleber F.X., Reindl I., Volk H.D. Systemic inflammation in patients with heart failure. Eur Heart J 1998, 19:761-765.
31. Rana J.S., Boekholdt S.M., Rider P.M., Jukema J.W., Luben R., Bingham S.A., et al. Differential leukocyte count and the risk of future coronary artery disease in healthy men and women: The EPIC-Norfolk Prospective Population Study. J Intern Med 2007, 262:678-689.
32. Wheeler J.G., Mussolino M.E., Gillum R.F., Danesh J. Associations between differential leukocyte count and incident coronary heart disease: 1764 incident cases from seven prospective studies of 30,374 individuals. Eur Heart J 2004, 25:1287-1292.
33. Arruda-Olson A.M., Reeder G.S., Bell M.R., Weston S.A., Roger V.L. Neutrophilia predicts death and heart failure after myocardial infarction: A community-based study. Circ Cardiovasc Qual Outcomes 2009, 2:656-662.
34. Gottdiener J.S., Arnold A.M., Aurigemma G.P., Polak J.F., Tracy R.P., Kitzman D.W., et al. Predictors of congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2000, 35:1628-1637.
35. Mann D.L., Young J.B. Basic mechanisms in congestive heart failure: Recognizing the role of proinflammatory cytokines. Chest 1994, 105:897-904.
36. Yndestad A., Damås J.K., Øie E., Ueland T., Gullestad L., Aukrust P. Systemic inflammation in heart failure-The whys and wherefores. Heart Fail Rev 2006, 11:83-92.
37. Ho K.K., Anderson K.M., Kannel W.B., Grossman W., Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993, 88:107-115.
38. Tracchi I., Ghigliotti G., Mura M., Garibaldi S., Spallarossa P., Barisione C., et al. Increased neutrophil lifespan in patients with congestive heart failure. Eur J Heart Fail 2009, 11:378-385.
39. Leone A.M., Giannico M.B., Bruno I., Giordano A., Zaccone V., Perfetti M., et al. Safety and efficacy of G-CSF in patients with ischemic heart failure: The CORNER (Cell Option for Recovery in the Non-Eligible patients for Revascularization) study. Int J Cardiol 2011, 150:75-78.
40. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105:1890-1896.
41. Dragu R., Huri S., Zuckerman R., Suleiman M., Mutlak D., Agmon Y., et al. Predictive value of white blood cell subtypes for long-term outcome following myocardial infarction. Atherosclerosis 2008, 196:405-412.